^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

CRY1 mutation

i
Other names: CRY1, Cryptochrome Circadian Regulator 1, Cryptochrome 1 (Photolyase-Like), Cryptochrome Circadian Clock 1, Cryptochrome-1, PHLL1, DSPD
Entrez ID:
Related biomarkers:
9ms
CRYL1 is a Potential Prognostic Biomarker of Clear Cell Renal Cell Carcinoma Correlated with Immune Infiltration and Cuproptosis. (PubMed, Technol Cancer Res Treat)
CRYL1 is a robust predictive marker for clinicopathological characteristics and survival status in ccRCC patients.
Journal
|
CRY1, Cryptochrome Circadian Regulator 1, • FDX1 (Ferredoxin 1) • LIAS (Lipoic Acid Synthetase)
|
CRY1 mutation
10ms
Bevacizumab increases the sensitivity of olaparib to homologous recombination-proficient ovarian cancer by suppressing CRY1 via PI3K/AKT pathway. (PubMed, Front Oncol)
Here, we demonstrated that anti-angiogenic agents, bevacizumab and cediranib, increased the sensitivity of olaparib in HRP EOC cells by suppressing HR activity. In addition, CRY1 inhibition also sensitized EOC cells to olaparib. These data suggested that anti-angiogenic agents and CRY1 inhibitors will be the promising candidate in the combination therapy with PARP inhibitors in HR-proficient EOC.
Journal • PARP Biomarker
|
RAD51 (RAD51 Homolog A) • CRY1, Cryptochrome Circadian Regulator 1,
|
CRY1 mutation
|
Avastin (bevacizumab) • Lynparza (olaparib) • Recentin (cediranib)
10ms
Impact of Long-Lasting Environmental Factors on Regulation Mediated by the miR-34 Family. (PubMed, Biomedicines)
Moreover, the apoptogenic capacity of miR-34 induced via phthalate administration in the testes has been shown to negatively influence germ cell proliferation. To conclude, as the oncostatic and positive neuromodulatory functions of the miR-34 family can be strongly influenced by environmental factors, their interactions should be taken into consideration in translational medicine.
Review • Journal
|
CCND1 (Cyclin D1) • MIR34A (MicroRNA 34a-5p) • CRY1, Cryptochrome Circadian Regulator 1, • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
|
CCND1 expression • CRY1 mutation • miR-34a expression
12ms
Circadian modulation of glucose utilization via CRY1-mediated repression of Pdk1 expression. (PubMed, J Biol Chem)
Furthermore, reduced CRY1 levels and the increased phosphorylation of PDK1 substrate were observed when cells were grown in suspension compared to cells grown in adhesion. Our data supports a model that the transcription-translation feedback loop can regulate the glucose metabolic pathway through Pdk1 gene expression according to the time of the day.
Journal
|
CRY1, Cryptochrome Circadian Regulator 1, • PDK1 (Pyruvate Dehydrogenase Kinase 1)
|
CRY1 mutation
1year
Dysregulated expression of slingshot protein phosphatase 1 (SSH1) disrupts circadian rhythm and WNT signaling associated to hepatocellular carcinoma pathogenesis. (PubMed, Aging (Albany NY))
The expression of SSH1, CLOCK, BMAL1 and β-catenin proteins were significantly downregulated in the SenAlight and SenAdark mice; this was more so in the SenAdark mice. This reveals a potential treatment approach for HCC patients.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CRY1, Cryptochrome Circadian Regulator 1, • ARNTL (Aryl Hydrocarbon Receptor Nuclear Translocator Like) • CLOCK (Clock Circadian Regulator) • WNT3 (Wnt Family Member 3)
|
CRY1 mutation
over1year
Comprehensive profiling of clock genes expression in hepatocellular carcinoma (HCC). (ASCO 2023)
This is the most extensive profiling study to investigate the expression of clock genes in HCC. Our data show that clock genes expression impacts patient survival and is associated with alterations in immune-related gene expression and TIS score which suggest a role in the modulation of anti-tumor immunity. These results support the clock pathway role as a oncogenic driver and its potential as a therapeutic target in HCC.
Tumor mutational burden • PD(L)-1 Biomarker • MSi-H Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • TERT (Telomerase Reverse Transcriptase) • PD-1 (Programmed cell death 1) • LAG3 (Lymphocyte Activating 3) • FGF3 (Fibroblast growth factor 3) • PD-L2 (Programmed Cell Death 1 Ligand 2) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • IDO1 (Indoleamine 2,3-dioxygenase 1) • CRY1, Cryptochrome Circadian Regulator 1, • WEE1 (WEE1 G2 Checkpoint Kinase) • ARNTL (Aryl Hydrocarbon Receptor Nuclear Translocator Like) • CLOCK (Clock Circadian Regulator) • PER1 (Period Circadian Clock 1) • CD80 (CD80 Molecule) • CD86 (CD86 Molecule) • NR1D1 (Nuclear Receptor Subfamily 1 Group D Member 1)
|
PD-L1 expression • MSI-H/dMMR • TERT mutation • CRY1 mutation
2years
2.4 GHz Electromagnetic Field Influences the Response of the Circadian Oscillator in the Colorectal Cancer Cell Line DLD1 to miR-34a-Mediated Regulation. (PubMed, Int J Mol Sci)
The effect of miR-34a on proliferation and migration was eliminated by RF-EMF exposure. In conclusion, RF-EMF strongly influenced regulation mediated by the tumour suppressor miR-34a on the peripheral circadian oscillator in DLD1 cells.
Preclinical • Journal
|
BIRC5 (Baculoviral IAP repeat containing 5) • MIR34A (MicroRNA 34a-5p) • PER2 (Period Circadian Regulator 2) • CRY1, Cryptochrome Circadian Regulator 1, • ARNTL (Aryl Hydrocarbon Receptor Nuclear Translocator Like) • CLOCK (Clock Circadian Regulator) • SIRT1 (Sirtuin 1)
|
BIRC5 expression • CRY1 mutation
2years
Downregulation of Crystallin Lambda 1 is a New Independent Prognostic Marker in Clear Cell Renal Cell Carcinoma. (PubMed, Pharmgenomics Pers Med)
Finally, GSEA revealed that CRYL1 expression levels (P < 0.001) were associated with fatty acid metabolism, G2M checkpoint delays, and epithelial-mesenchymal transitions in ccRCC. Our study found that lower levels of CRYL1 expression were linked to unfavorable clinicopathological characteristics and worse prognoses, and CRYL1 could serve as a new target for the treatment of ccRCC, which is useful for personalized medicine.
Journal
|
CRY1, Cryptochrome Circadian Regulator 1,
|
CRY1 mutation